Af­ter sell­ing Rubra­ca, Clo­vis On­col­o­gy un­veils CRL for po­ten­tial la­bel ex­pan­sion

Clo­vis On­col­o­gy is fac­ing yet an­oth­er set­back with the FDA giv­ing the bat­tled com­pa­ny a com­plete re­sponse let­ter and re­ject­ing a po­ten­tial la­bel ex­pan­sion for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER